Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma Patients

Inclusion criteria: * Diagnosis of melanoma (The International Classification of Diseases, 9th Revision \[ICD-9\] 172.x \& 10th revision \[ICD-10\] C43 or D03x). * Pathologic stage IV at initial diagnosis on or after 01 January 2011. * First-line treatment with IO monotherapy or combination therapy (nivolumab, pembrolizumab, ipilimumab + nivolumab) or TT combination therapy (dabrafenib + trametinib, vemurafenib+cobimetinib, encorafenib+binimetinib) on or after 01 January 2014. * Evidence of a BRAF test. * Evidence of a BRAF-positive result prior to or up to 30 days after first-line (1L) therapy initiation. * At least 18 years of age at the time of initiation of 1L treatment. Exclusion criteria: * Documented receipt of a clinical trial treatment for cancer at any time on or after 01 January 2014. * Diagnosis of a second primary cancer or secondary cancer following initiation of 1L metastatic melanoma (MM) treatment.